Search

Displaying results 431 - 440 of 10000 in total
  1. Target

    Apelin receptor

    go.drugbank.com/bio_entities/BE0013166
    TargetHumans

    G protein-coupled receptor for peptide hormones apelin (APLN) and apelin receptor early endogenous ligand (APELA/ELA), that plays a role in the regulation of normal cardiovascular function and fluid homeostasis … When acting as apelin receptor, activates both G(i) protein pathway that inhibits adenylate cyclase activity, and the beta-arrestin pathway that promotes internalization of the receptor (PubMed:11090199

    Polypeptides: Apelin receptorSynonyms: Angiotensin receptor-like 1, G protein-coupled receptor APJ
  2. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical … Anthralin has also been studied in the treatment of warts, showing promising results [A32307].

    Products: Anthraforte 2 Ointment 2%, Anthraforte 1 Ointment 1%
  3. Drug

    Tavolixizumab

    go.drugbank.com/drugs/DB15042
    Investigational

    Tavolixizumab is under investigation in clinical trial NCT02318394 (A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors).

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENSTNFRSF4 (TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 4, OX40, CD134)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY GAMMA1 HEAVY CHAIN (1-451) (CHIMERIC, VH (MUS MUSCULUS IGHV3-8*02 -(IGHD)-HOMO SAPIEN
  4. Indication

    Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma

    go.drugbank.com/conditions/DBCOND0162925
    Drugs: Sacituzumab govitecan
    Synonyms: Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma
  5. Indication

    Acute nephrosis

    go.drugbank.com/conditions/DBCOND0020416
    Drugs: Albumin human
    Synonyms: ATIN - Acute tubulo-interstitial nephritis
  6. Drug

    Zinc

    go.drugbank.com/drugs/DB01593
    ApprovedInvestigational

    In addition to the above, recent review articles have already demonstrated the important role of zinc in the pathophysiology and treatment of affective disorders, plus discussed the potential value of … zinc as a marker of these diseases [L2097].

    Mixtures: BLACKMORES teen multi for GUYS capsule, BLACKMORES teen multi for GIRLS capsuleProducts: ZINCO-K 15MG/5 ML 28 KASIK SURUP, ZINCO-K 15MG/5 ML KASIK SURUP, 20 ADET
  7. Drug

    Anbenitamab

    go.drugbank.com/drugs/DB18411
    Investigational

    Synonyms: IMMUNOGLOBULIN G1 (369-SERINE,371-ALANINE,408-LYSINE,410-VALINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2 DOMAIN IV)(HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB 4D5 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS, FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4
  8. Target

    Prostacyclin receptor

    go.drugbank.com/bio_entities/BE0000475
    TargetHumans

    Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase

    Polypeptides: Prostacyclin receptorSynonyms: PGI receptor, PGI2 receptor
  9. Target

    Glucagon receptor

    go.drugbank.com/bio_entities/BE0000527
    TargetHumans

    G protein-coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis.

    Polypeptides: Glucagon receptorFunction: glucagon receptor activity
  10. Target

    Erythropoietin receptor

    go.drugbank.com/bio_entities/BE0000654
    TargetHumans

    Receptor for erythropoietin, which mediates erythropoietin-induced erythroblast proliferation and differentiation (PubMed:10388848, PubMed:2163695, PubMed:2163696, PubMed:8662939, PubMed:9774108).

    Polypeptides: Erythropoietin receptorFunction: erythropoietin receptor activity